Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
$26.2 million in U.S. neffy ® net product revenue in Q2 2026; total U.S. epinephrine market share for Type 1 allergies of 5% and 8% share within field-targeted accounts Commercial investment...
San Diego, California--(Newsfile Corp. - August 13, 2026) - Robbins LLP reminds shareholders that a securities class action has been filed on behalf of all investors who purchased or otherwise acquired...
A securities class action alleges ARS Pharmaceuticals paired specific, confident statements about a July 1, 2026 CVS Caremark formulary date with only generalized risk language, leaving SPRY investors...
NEW YORK , Aug. 13, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against ARS Pharmaceuticals, Inc. ("ARS" or the "Company") (NASDAQ: SPRY). Such investors...
Barchart Research What to Expect from SPRY Earnings SPRY Generated August 12, 2026 Current Price $6.05 EPS Estimate $$-0.55 Consensus Rating Strong Buy Average Move 8.49% ARS Pharmaceuticals Nears Profitability...
Allegations focus on ARS Pharmaceuticals' alleged failure to disclose the risk that CVS Caremark's rigid formulary system could push a neffy coverage decision to January 2027, missing the summer...
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
NEW YORK , Aug. 11, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of ARS Pharmaceuticals, Inc. (NASDAQ:...
NEW YORK , Aug. 11, 2026 /PRNewswire/ -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against ARS Pharmaceuticals...